Hepatology

Results of the systematic review and meta-analysis support the use of pan-genotypic DAA regimens for the treatment of chronic HCV in adolescents and children ≥ 3 years of age.

The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.

Study results called attention to the negative impact of living in a rural residence and a highly dependent neighborhood on HCV screening by 2 years of age in children born to HCV RNA positive mothers.

Although there was a greater prevalence of ALD and MetALD among male study participants, females had a greater risk of mortality from both SLD phenotypes, highlighting a potentially greater impact of alcohol consumption on women with liver disease than men.

Results showed a 12% incidence of HCV in pregnancy with a preterm birth rate nearly double the national average, although no statistically significant difference in preterm birth rates was observed between HCV-positive and HCV-negative patients.

Test your knowledge with this clinician quiz! In this quiz, we test your knowledge of updates in the management of hepatitis C virus based on the AASLD/IDSA 2023 guidance update.

Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.

Sustained virologic response and several sociodemographic factors were found to be significantly associated with long-term improvements in health-related quality of life in patients with HCV.

The XGBoost machine learning model outperformed other AI and logistic regression models for predicting DAA failure, with an AUROC of 1.000 in the training dataset and 0.803 in the validation dataset.

Consuming a 5mg piperine capsule once daily for 12 weeks was linked to several pharmacological improvements in patients with NAFLD.

Patients in the integrated and standard care treatment arms reported similar SCL-10 scores indicative of psychological stress and symptom burden, both at baseline and after the completion of DAA treatment.

Screening for liver fibrosis was associated with sustained improvements in alcohol consumption, diet, weight, and exercise in individuals at risk of ALD and MASLD.

Liver transplantation after prolonged preservation with dual hypothermic oxygenated machine perfusion yielded similar outcomes to standard perfusion, showing no compromised donor liver quality and equal safety for recipients.

Although the overall response rate among the cohort was 96.4%, this figure dropped as low as 66.7% when accounting for male gender, GT3 infection, cirrhosis, obesity, and non-response to previous therapy.

Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.

Investigators examined data from the Global Burden of Disease, Injuries, and Risk Factors study 2019 to describe the global, regional, and national burden of liver cancer due to hepatitis C since 1990.

The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.

Patients with lean NAFLD had fewer metabolic comorbidities but maintained similar risk of NASH, cirrhosis, nonliver cancer, and mortality compared to their overweight and obese counterparts.

We sat down with Tatyana Kushner, MD, BSCE to discuss findings from her study comparing IVF treatment in women with and without liver disease.

Our December 2023 month in review highlights top news in HCV screening, treatment with DAAs, and MASLD risk factors.

IVF treatment and pregnancy outcomes were not significantly different between patients with and without liver disease who received assisted reproductive technology treatment.

Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.

Reduced fecal concentrations of short- and branched-chain fatty acids, secondary bile acids, and tryptophan metabolites were associated with compositional microbiome dysbiosis and risk of postoperative infection.

Greater selenium and lead exposure were associated with an increased risk of MASLD, with further analysis suggesting potential synergistic interactions between different metals and their joint effects on MASLD risk.

More than half of study participants were enrolled in the patient portal and 98% were classified as passive users, but only moderately active use of the patient portal was associated with a reduced risk of readmission.

Although no differences were observed in the safety and efficacy of FDA-approved combination DAA therapies, female participants reported numerically more adverse events than male participants.

Results from the systematic review and meta-analysis demonstrated the positive effect of DAA therapy on overall survival, HCC-free survival, and liver function among patients with HCV decompensated cirrhosis compared to a non-DAA control group.

Specific interactions between binge drinking, genetic risk, and diabetes mellitus were found to significantly influence the risk of alcohol-related cirrhosis.

The New Drug Application submission is supported by data from a pair of phase 3 studies, a long-term open-label study, and prior phase 2 studies. Cymabay has also requested Priority Review of the NDA.

Patients with HCV who underwent automated routine screening and the addition of a clinical pharmacist to the interdisciplinary patient care model completed treatment and achieved SVR at a greater rate than patients who were not exposed to the study intervention.